ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program

Fabry Disease Clinical Trial

— ScreenPlus  

Official title:

ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT05368038
• Other study ID #: 19-10-212
• Secondary ID: R01HD073292
• Status: Enrolling by invitation
• Start date: May 10, 2021
• Est. completion date: July 31, 2026

Study information

• Verified date: June 2024
• Source: Albert Einstein College of Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

ScreenPlus is a consented, multi-disorder pilot newborn screening program implemented in conjunction with the New York State Newborn Screening Program that provides families the option to have their newborn(s) screened for a panel of additional conditions. The study has three primary objectives: 1) define the analytic and clinical validity of multi-tiered screening assays for a flexible panel of disorders, 2) determine disease incidence in an ethnically diverse population, and 3) assess the impact of early diagnosis on health outcomes. Over a five-year period, ScreenPlus aims to screen 175,000 infants born in nine high birthrate, ethnically diverse pilot hospitals in New York for a flexible panel of 14 rare genetic disorders. This study will also involve an evaluation of the Ethical, Legal and Social issues pertaining to NBS for complex disorders, which will be done via online surveys that will be directed towards ScreenPlus parents who opt to participate and qualitative interviews with families of infants who are identified through ScreenPlus.

Description:

Soon after birth, all babies born in the United States have a newborn screening (NBS) test to check for certain medical conditions. All babies are screened, even if they appear healthy, because most of these conditions have no obvious physical findings in a newborn and might otherwise be diagnosed only after the development of serious problems, such as brain damage, organ damage, or death. In fact, NBS has been an integral part of preventable health care for over five decades, ever since the discovery that phenylketonuria is an easily diagnosed, preventable cause of intellectual disability.

Over the past two decades, there have been dramatic advances in screening technology, with a resulting increase in the number and complexity of disorders on NBS panels. This enhanced ability to screen brings questions about what types of disorders are appropriate for NBS. To that end, the Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC) was established in 2003 to make evidence-based recommendations at the national level regarding the suitability of various disorders for NBS. At present, the Recommended Uniform Screening Panel, or the RUSP, includes 35 core disorders. The RUSP nomination process uses information about disease incidence and severity, natural history, benefits of early detection, safety and efficacy of treatment, analytic and clinical validity of the screening tests, as well as consideration of potential harms associated with screening and public health impact to determine whether a particular disorder is appropriate for NBS. However, there are many disorders for which this data is insufficient or missing. There are other disorders that challenge traditional NBS criteria by having predominantly later-onset phenotypes, poorly defined natural history, or unclear treatment outcomes. As these potentially life-threatening disorders might benefit from early detection, gathering and analyzing this data is both critical and timely. Accordingly, there is a great deal of interest in pilot NBS studies as a means to gather objective evidence about whether a disorder is appropriate for widespread screening.

ScreenPlus is a comprehensive, fluid, pilot NBS program that will screen 175,000 consented infants for specific disorders that are under consideration for universal NBS. This study will generate critical data about the validity of testing for these candidate disorders and provide estimates of disease incidence in a large, ethnically diverse population. The investigators will evaluate different consent and engagement models, including direct, in-person interaction and the use of a novel E-Consent framework to educate parents about pilot NBS. The investigators will also collect nuanced information about the ethical implications of NBS, by conducting qualitative interviews with parents of children who have received a positive or uncertain NBS result. Parents who are eligible to participate in ScreenPlus will also have the opportunity to complete a flexible set of surveys of parent opinions about expanded NBS, research using dried blood spots, and other relevant topics. Furthermore, newborns who screen positive will be followed by a ScreenPlus physician. Through thoughtful collaboration with disease experts, the investigators will help systematically collect disease specific measures through detailed long-term follow-up which will enable us to critically evaluate how affected children identified through ScreenPlus are faring, allowing objective assessment of the impact early diagnosis has on outcome.

The investigators will share this important data with the NBS community, including the ACHDNC, to help inform objective decision-making about widespread screening recommendations. The ScreenPlus panel is fluid and disorders may be added/removed as disorders satisfy the study inclusion criteria or are added to the RUSP and/or the New York State routine NBS panel. Additionally, recognizing that the NIH, advocacy groups, academics, and private industry all share a desire for clean, consented pilot NBS data, the investigators created a unique financial infrastructure. This investigator-driven arrangement permits all stakeholders to obtain aggregate data of interest in a mutually beneficial and cost-effective manner. ScreenPlus is guided by Scientific and Community Advisory Boards, who are comprised of rare disease experts, biochemistry specialists, physicians, bioethicists, and patient advocates. Overall, the investigators anticipate that ScreenPlus will become the premier consented pilot NBS program in the United States.

In sum, ScreenPlus will provide critical data about the appropriateness of NBS for candidate disorders, the feasibility and effectiveness of consented screening models, and parent informational needs and preferences as they relate to NBS for complex disorders.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 175000
• Est. completion date: July 31, 2026
• Est. primary completion date: July 31, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A to 4 Weeks

Eligibility

Inclusion Criteria:

• All newborn infants born at a ScreenPlus pilot hospital

• Infants who are less than four weeks old, regardless of sex, gestational age, or health status.

Exclusion Criteria:

• A newborn screening sample is unavailable

• Infants who are more than four weeks old

Related Conditions & MeSH terms

• Acid Sphingomyelinase Deficiency
• Cerebrotendinous Xanthomatosis
• Fabry Disease
• Gangliosidoses
• Gangliosidosis, GM1
• Gaucher Disease
• GM1 Gangliosidosis
• Leukodystrophy, Metachromatic
• Lysosomal Acid Lipase Deficiency
• Metachromatic Leukodystrophy
• Mucopolysaccharidoses
• Mucopolysaccharidosis II
• Mucopolysaccharidosis III
• Mucopolysaccharidosis III-B
• Mucopolysaccharidosis IV
• Mucopolysaccharidosis IV A
• Mucopolysaccharidosis VI
• Mucopolysaccharidosis VII
• Neuronal Ceroid-Lipofuscinoses
• Niemann-Pick Disease, Type C
• Niemann-Pick Diseases
• Pick Disease of the Brain
• Wolman Disease
• Xanthomatosis, Cerebrotendinous

Intervention

Diagnostic Test:
• Confirmatory Testing
All positive screens will be referred using standard notification procedures, where the New York State NBS reporting team contacts the ScreenPlus site medical geneticist, who will contact the newborn's pediatrician and family. The initial evaluation will include a clinical examination and confirmatory molecular studies, enzymatic and biomarker studies, when available. All aspects of the confirmatory testing will be at no cost to the participants. If confirmed to have a ScreenPlus disorder, the investigators will counsel the family and help connect them with treatment, clinical trials and disease specialists. The investigators will also provide emotional and social support resources to help in this journey.

Locations

Country	Name	City	State
United States	Jack D. Weiler Hospital	Bronx	New York
United States	ScreenPlus Coordinating Core, Children's Hospital at Montefiore	Bronx	New York
United States	Maimonides Medical Center	Brooklyn	New York
United States	NYU Langone Hospital - Brooklyn	Brooklyn	New York
United States	North Shore University Hospital	Manhasset	New York
United States	Mount Sinai Hospital	New York	New York
United States	Mount Sinai West	New York	New York
United States	NYU Langone Health - Tisch Hospital	New York	New York
United States	Long Island Jewish Medical Center	Queens	New York

Sponsors (16)

Lead Sponsor

Collaborator

Albert Einstein College of Medicine

Alexion, AstraZeneca Rare Disease, Ara Parseghian Medical Research Fund, BioMarin Pharmaceutical, Cure Sanfilippo Foundation, Dana's Angels Research Trust, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Genzyme, a Sanofi Company, Orchard Therapeutics, Passage Bio, Inc., Sio Gene Therapies, Takeda, The FireFly Fund, The Noah's Hope - Hope 4 Bridget Family Foundations, Travere Therapeutics, Inc., Ultragenyx Pharmaceutical Inc

Country where clinical trial is conducted

United States, 

References & Publications (2)

Calonge N, Green NS, Rinaldo P, Lloyd-Puryear M, Dougherty D, Boyle C, Watson M, Trotter T, Terry SF, Howell RR; Advisory Committee on Heritable Disorders in Newborns and Children. Committee report: Method for evaluating conditions nominated for population-based screening of newborns and children. Genet Med. 2010 Mar;12(3):153-9. doi: 10.1097/GIM.0b013e3181d2af04. — View Citation

Wasserstein MP, Caggana M, Bailey SM, Desnick RJ, Edelmann L, Estrella L, Holzman I, Kelly NR, Kornreich R, Kupchik SG, Martin M, Nafday SM, Wasserman R, Yang A, Yu C, Orsini JJ. The New York pilot newborn screening program for lysosomal storage diseases: Report of the First 65,000 Infants. Genet Med. 2019 Mar;21(3):631-640. doi: 10.1038/s41436-018-0129-y. Epub 2018 Aug 10. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluate the accuracy of the screening assays.	Accuracy of the screening assay will be defined in terms of positive predictive value (proportion of confirmed cases comparative to the total number of infants who screened positive).	Through study completion up to 5 years.
Primary	Define disease incidence in an ethnically diverse population.	Disease incidence will be calculated as the proportion of infants with a disorder comparative to the total population of infants screened.	Through study completion up to 5 years.

External Links

•   Official ScreenPlus information page on the Albert Einstein College of Medicine website.